Dynein	O
light	O
chain	O
1	O
,	O
a	O
p21	O
-	O
activated	O
kinase	O
1	O
-	O
interacting	O
substrate	O
,	O
promotes	O
cancerous	B-Cancer
phenotypes	O
.	O

We	O
identified	O
dynein	O
light	O
chain	O
1	O
(	O
DLC1	O
)	O
as	O
a	O
physiologic	O
substrate	O
of	O
p21	O
-	O
activated	O
kinase	O
1	O
(	O
Pak1	O
)	O
.	O

Pak1	O
-	O
DLC1	O
interaction	O
plays	O
an	O
essential	O
role	O
in	O
cell	B-Cell
survival	O
,	O
which	O
depends	O
on	O
Pak1	O
'	O
s	O
phosphorylation	O
of	O
DLC1	O
on	O
Ser88	O
.	O

Pak1	O
associates	O
with	O
the	O
complex	O
of	O
DLC1	O
and	O
BimL	O
,	O
a	O
proapoptotic	O
BH3	O
-	O
only	O
protein	O
,	O
and	O
phosphorylates	O
both	O
proteins	O
.	O

Phosphorylation	O
of	O
BimL	O
by	O
Pak1	O
prevents	O
it	O
from	O
interacting	O
with	O
and	O
inactivation	O
of	O
Bcl	O
-	O
2	O
,	O
an	O
antiapoptotic	O
protein	O
.	O

Overexpression	O
of	O
DLC1	O
but	O
not	O
DLC1	O
-	O
Ser88Ala	O
mutant	O
promotes	O
cancerous	B-Cancer
properties	O
of	O
breast	B-Cell
cancer	I-Cell
cells	I-Cell
.	O

DLC1	O
protein	O
level	O
is	O
elevated	O
in	O
more	O
than	O
90	O
%	O
of	O
human	O
breast	B-Cancer
tumors	I-Cancer
.	O

The	O
regulation	O
of	O
cell	B-Cell
survival	O
functions	O
by	O
Pak1	O
-	O
DLC1	O
interaction	O
represents	O
a	O
novel	O
mechanism	O
by	O
which	O
a	O
signaling	O
kinase	O
might	O
regulate	O
the	O
cancerous	B-Cancer
phenotypes	O
.	O

